Last year, Novavax (NASDAQ:NVAX) was one of the strongest stocks in the entire market. The micro cap ran up from $4 a share in January all the way to $119 in December. Then in 2021, the stock almost tripled after Novavax reported positive phase 3 data in its U.K. study for a COVID-19 vaccine. After hitting $330 a share, investors were whipsawed as the stock price dropped to $149.
Is Novavax stock a buy today? Corinne Cardina, the Bureau Chief for Healthcare and Cannabis at Fool.com, and Motley Fool contributor Taylor Carmichael discuss this vaccine specialist. This segment was recorded live on March 5.
Should you invest $1,000 in Novavax, Inc. right now?
Before you consider Novavax, Inc., you'll want to hear this.
Investing legends and Motley Fool Co-founders David and Tom Gardner just revealed what they believe are the 10 best stocks for investors to buy right now... and Novavax, Inc. wasn't one of them.
The online investing service they've run for nearly two decades, Motley Fool Stock Advisor, has beaten the stock market by over 4X.* And right now, they think there are 10 stocks that are better buys.
*Stock Advisor returns as of February 24, 2021
Corinne Cardina: All right, we're going to talk about some biotech stocks. Taylor, let's try to do two minutes on each of these so we have time to get to the last question. I know the time just goes by so quickly. [laughs] We're going to start with Novavax because we've touched on it. This is one that has not yet gotten that FDA authorization, but it does have a COVID-19 vaccine that has given us phase 3 info. What should investors know about Novavax in two minutes or less?
Taylor Carmichael: Novavax has been a great stock. Last year it was the No. 1 or No. 2 stock in the entire stock market. It's been an amazing stock for people. This year it was way up, it doubled quickly after they had positive phase 3 data. And it's been slaughtered, the nice word for it, in the last two weeks, I think. If you have not bought Novavax before, now is a good time to be doing that research there because I mean, this is a company that has billions in revenues that are coming in this year. This is already contracted, because COVID-19 is not being sold to insurance companies, is not being sold to you and me, it's being sold to governments. Governments are making deals with these companies, and all these deals have already been made for the most part. They have locked in revenues for this year. Novavax, we're seeing a transition from an unprofitable company with no drugs on the market. This year they'll definitely have their COVID-19. I think it's a lock for Emergency Use Authorization. They're going to get it and they're going to get it within a couple of months I think.
Cardina: Yes
Carmichael: Not just in the U.S. Novavax has an amazing worldwide network of deals in place. They have got a deal in the U.K., they've got a deal in Australia, they've got a deal in Canada, they've got a deal in the Third World. They're going to make billions this year. The stock's about 50 percent off from its highs, I think.
Cardina: Not to mention they have a flu vaccine that has been proven superior to the flu vaccine that's on the market. They've talked about the possibility of combining. It won't happen this year, but in the long term they could combine flu vaccine with COVID-19 vaccine, which is really an amazing concept.
10 stocks we like better than Novavax
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Novavax wasn't one of them! That's right -- they think these 10 stocks are even better buys.
